Literature DB >> 55114

Terminal dilution purification of adenovirus prototypes, and the antigenic relationship between types 4, 16 and 14.

R Wigand.   

Abstract

Two terminal dilution purifications in HEK cells were performed with adenovirus prototypes of types 1 to 7, 12, 16, 19 and 9-15, and one terminal dilution with a freshly isolated type 8 strain. The antisera prepared against viruses after terminal dilution neutralized the original and the purified virus to the same extent, indicating the antigenic purity of the respective prototypes. Cross-reactions in neutralization with other types within the subgroup were also identical. Only the prototype of type 16 (Ch 79) showed a cross-neutralization with type 4, while four type 16 wild strains showed cross-neutralization with type 14, but none with type 4. The prototype (CH 79) is a "prime strain" in relation to the type 16 wild strains.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 55114     DOI: 10.1007/bf01318241

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  13 in total

1.  [ON THE CYTOPATHOGENIC EFFECT OF ADENOVIRUSES IN MAN].

Authors:  R WIGAND; H BAUER
Journal:  Arch Gesamte Virusforsch       Date:  1964-06-17

2.  Observations on some little-known adenoviruses.

Authors:  L ROSEN; J F HOVIS; J A BELL
Journal:  Proc Soc Exp Biol Med       Date:  1962-10

3.  THE ENTEROVIRUSES; Committee on the Enteroviruses, National Foundation for Infantile Paralysis.

Authors: 
Journal:  Am J Public Health Nations Health       Date:  1957-12

4.  Serotype composition of the adenovirus group.

Authors:  W P ROWE; J W HARTLEY; R J HUEBNER
Journal:  Proc Soc Exp Biol Med       Date:  1958-02

5.  Further observation on typing adenoviruses and a description of two possible additional serotypes.

Authors:  L ROSEN; J F HOVIS; J A BELL
Journal:  Proc Soc Exp Biol Med       Date:  1962 Aug-Sep

6.  Specificity of hemagglutination-inhibition with adenovirus particles of subgroup I and III.

Authors:  R Wigand; D Keller
Journal:  Arch Gesamte Virusforsch       Date:  1974

7.  Detection of oncornavirus-like particles in HeLa cells. I. Fine structure and comparative morphological classification.

Authors:  H Gelderblom; H Bauer; H Ogura; R Wigand; A B Fischer
Journal:  Int J Cancer       Date:  1974-02-15       Impact factor: 7.396

8.  [Serologically intermediary adenovirus strains].

Authors:  R Wigand
Journal:  Arch Gesamte Virusforsch       Date:  1965

9.  Serologically intermediate adenovirus strains: a regular feature of group II adenoviruses.

Authors:  R Wigand; D Fliedner
Journal:  Arch Gesamte Virusforsch       Date:  1968

10.  [Laboratory procedures in adenoviruses. II. Sensitivity of various cell cultures as determined by endpoint titration (author's transl)].

Authors:  R Wigand; R Schulz
Journal:  Zentralbl Bakteriol Orig A       Date:  1975
View more
  6 in total

1.  Does adenovirus subtype 7a exist?

Authors:  R Wigand
Journal:  Arch Virol       Date:  1976       Impact factor: 2.574

2.  The kinetics of adenovirus infection and spread in cell cultures infected with low multiplicity.

Authors:  R Wigand; G Kümel
Journal:  Arch Virol       Date:  1977       Impact factor: 2.574

3.  Immunological and biochemical characterization of human adenoviruses from subgenus B. I. Antigenic relationships.

Authors:  R Wigand; N Sehn; J C Hierholzer; J C de Jong; T Adrian
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

4.  Immunological relationship among human adenoviruses of subgenus D.

Authors:  R Wigand; D Keller; I Werling
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

5.  Computational analysis of four human adenovirus type 4 genomes reveals molecular evolution through two interspecies recombination events.

Authors:  Shoaleh Dehghan; Jason Seto; Elizabeth B Liu; Michael P Walsh; David W Dyer; James Chodosh; Donald Seto
Journal:  Virology       Date:  2013-06-10       Impact factor: 3.616

6.  The susceptibility of Vero cell cultures for human adenoviruses.

Authors:  P Hasler; R Wigand
Journal:  Med Microbiol Immunol       Date:  1978       Impact factor: 3.402

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.